首页> 美国卫生研究院文献>BMC Ophthalmology >Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland

【2h】

Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland

机译：与兰尼单抗相比接受aflibercept治疗的患者的注射频率和医疗保健费用：来自瑞士的新真实证据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundPrevious analyses of real-life data indicated that injection frequency and health care costs did not differ for anti-VEGF treatment with aflibercept and ranibizumab. The objective of this study was to investigate whether this finding persisted when analysing a longer time period after licensing.

机译：背景以往对现实生活数据的分析表明，使用abribercept和兰尼单抗的抗VEGF治疗的注射频率和医疗保健费用没有差异。这项研究的目的是调查在许可后较长的时间段内，这一发现是否持续。

著录项

期刊名称 BMC Ophthalmology
作者
Oliver Reich; Martin K. Schmid; Roland Rapold; Lucas M. Bachmann; Eva Blozik;
展开▼
作者单位

展开▼
年(卷),期 2017(17),-1
年度 2017
页码 234
总页数 8
原文格式 PDF
正文语种
中图分类眼科学;
关键词
Claims data Health insurance Cost analysis Macular degeneration Aflibercept Ranibizumab;

机译：索赔数据;健康保险;成本分析;黄斑变性;Aflibercept;Ranibizumab;

相似文献

外文文献
中文文献
专利

1. Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland [J] . Oliver Reich, Martin K. Schmid, Roland Rapold, BMC Ophthalmology . 2017,第1期

机译：与兰尼单抗相比，接受aflibercept治疗的患者的注射频率和医疗保健费用：瑞士的新真实证据
2. Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland [J] . Oliver Reich, Martin K. Schmid, Roland Rapold, BMC Ophthalmology . 2017,第1期

机译：与兰尼单抗相比，接受aflibercept治疗的患者的注射频率和医疗保健费用：瑞士的新真实证据
3. Patients with Central Retinal Vein Occlusion require fewer injections when treated with aflibercept compared to ranibizumab using a treat-and-extend regimen: A prospective double-masked study [J] . de Salles Manuel Casselholm, Amren Urban, Kvanta Anders P., Investigative ophthalmology & visual science . 2017,第8期

机译：中央视网膜静脉闭塞的患者在使用治疗和延伸方案的ranibizumab与ranibizumab相比，用aflibercepe治疗时需要更少的注射剂：一项潜在的双屏蔽研究
4. The Effects of Organizational Factors on Healthcare IT Adoption Costs: Evidence from New York Nursing Homes [C] . Avgar A., Hitt L.M., Tambe P. System Sciences (HICSS-43), 2010 . 2010

机译：组织因素对医疗保健IT采纳成本的影响：来自纽约疗养院的证据
5. Comparing Healthcare Resource Use and Costs for Patients with Normal Tension Glaucoma Across Levels of Severity: A Nationally Representative Sample of Commercially Insured US Adults Age 40 and Older [D] . ?Beal, Brennan T. 2020

机译：在整个严重程度的医疗资源利用和成本与患者正常眼压性青光眼比较：具有全国代表性的商业样本被保险人的美国成年人 40岁及以上
6. Comparing Treatment Persistence Healthcare Resource Utilization and Costs in Adult Patients with Major Depressive Disorder Treated with Escitalopram or Citalopram [O] . Eric Q. Wu, *, Paul E. Greenberg, 2011

机译：依西酞普兰或西酞普兰治疗的重度抑郁症成年患者的治疗持久性医疗资源利用和费用的比较
7. Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland [O] . Oliver Reich, Martin K. Schmid, Roland Rapold, 2017

机译：与Ranibizumab相比，用AfliBibelped治疗的患者注射频率和医疗费用：来自瑞士的新现实证据

Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅